Biostar Pharmaceuticals, Inc. provided earnings guidance for 2013. The company announced that its preliminary estimate that, based on the company's current review of the last fiscal year's results, its 2013 revenue growth is expected to exceed by 20% year over year while the company expects to achieve break even or slightly profitable operating results, as compared with a nearly $21.8 million loss from operations in 2012.